82 Investor presentation First six months of 2025 Oral semaglutide 25 submitted in profile broadly similar to Wegovy OASIS 4 trial enrolled 306 people with overweight or obesity 1 R 2:1 Week Oral semaglutide 25 mg 0 Dose escalation Placebo Treatment maintenance 64 7 weeks follow-up Trial objective • Confirm superiority of once-daily oral semaglutide 25 mg vs placebo Co-primary endpoint • Relative change in body weight (%) from baseline to 64 weeks • Achievement of ≥ 5% weight loss * Estimated means 1 BMI: ≥ 30 kg/m 2 or ≥ 27 kg/m 2 and ≥1 comorbidity. Excludes diabetes diagnosis or HbA1c ≥ 6.5% BMI: Body mass index; HbA 1c : Haemoglobin A 1C ; Sema: Semaglutide; US: United States; WL: Weight loss Note: Trial also included lifestyle intervention, with a 500 kcal/day deficit diet and 150 min/week physical activity. Data shown is tria Source: Novo Nordisk data on file
Download PDF file